Dresden, Germany

Alvin Thomas

This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignee: Denovomatrix Gmbh. Active years: 2021-2023.


% Patents Active = 100.0

 

Average Co-Inventor Count = 3.7

ph-index = 1


Company Filing History:


Years Active: 2021-2023

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Alvin Thomas

Introduction

Alvin Thomas is a notable inventor based in Dresden, Germany. He has made significant contributions to the field of biomedical engineering through his innovative patents. With a total of 2 patents, his work focuses on developing advanced materials for various applications.

Latest Patents

One of Alvin Thomas's latest patents is the "Non-covalently assembled biomatrix layer." This invention provides a biomatrix layer that includes a sulfated oligosaccharide and a peptide-polyethylene glycol-conjugate. The biomatrix layer is designed for use in biomedical applications such as neuroprostheses, biosensors, nerve grafts, cell culture, and drug delivery. Another significant patent is the "Non-covalently assembled conductive hydrogel," which comprises a polystyrene sulfonate compound and a conjugate of polyethylene glycol and a linker oligopeptide. This hydrogel has potential applications in various electronic and biomedical fields.

Career Highlights

Alvin Thomas works at Denovomatrix GmbH, where he continues to push the boundaries of innovation in biomaterials. His research and inventions have the potential to revolutionize the way we approach biomedical applications.

Collaborations

Alvin collaborates with talented individuals such as Yixin Zhang and Richard Wetzel, contributing to a dynamic research environment that fosters innovation.

Conclusion

Alvin Thomas's work exemplifies the spirit of innovation in the field of biomedical engineering. His patents not only highlight his creativity but also pave the way for future advancements in medical technology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…